<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108508</url>
  </required_header>
  <id_info>
    <org_study_id>BIOSILICI</org_study_id>
    <nct_id>NCT03108508</nct_id>
  </id_info>
  <brief_title>Non-inferiority Bioavailabilty Study of 3 Silicon-rich Supplements</brief_title>
  <acronym>BIOSILICI</acronym>
  <official_title>Randomized, Crossover, Double Blinded, Non-inferiority Study of Three Products Rich in Organic Silicon, in Postprandrial Situation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technological Centre of Nutrition and Health, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SILICIUM ESPAÑA LABORATORIOS SLU</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Sant Joan de Reus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Rovira i Virgili</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technological Centre of Nutrition and Health, Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to evaluate the non-inferiority of the absorption
      parameters of three silicon supplements in human volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the present study is to evaluate the non-inferiority of the absorption
      parameters of three silicon supplements in human volunteers.

      Participants: 5 healthy men over 18 years old, with normal serum creatinine levels. Treatment
      consists of one product consumption every week, and measuring postprandrial response at 0,
      30, 60, 90, 120, 180, 240 and 360 min, in blood, and urine in two periods of three hours
      each.

      The statistical analysis will follow the principles specified in the guidelines of the ICHE
      and CPMP/EWP/908/99 ICHE Points to Consider on Multiplicity Issues in Clinical Trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>concentration of sillicium in urine samples</measure>
    <time_frame>Urine will be collected in two 3-h collections (0-180min and 181-360 min) in two separate containers at Visit 1, Visit 2 and Visit 3 (1 week between visits)</time_frame>
    <description>concentration of sillicium in urine samples will be measured by inductively coupled plasma optical emission spectrometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>concentration of sillicium in plasma</measure>
    <time_frame>Blood samples will be collected to determine baseline plasma silicon value (time 0 min = T0). After ingestion of one of the study products, additional blood samples will be collected at 30, 60, 90 and 120 min at Visit 1, Visit 2 and Visit 3</time_frame>
    <description>concentration of silicon in blood/plasma samples will be measured by inductively coupled plasma optical emission spectrometry.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Absorption; Disorder</condition>
  <arm_group>
    <arm_group_label>Prod1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G5 Siliplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prod2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orgono Powder®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prod3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G7 ALOE</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prod1</intervention_name>
    <description>60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.</description>
    <arm_group_label>Prod1</arm_group_label>
    <other_name>G5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prod2</intervention_name>
    <description>1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon</description>
    <arm_group_label>Prod2</arm_group_label>
    <other_name>Orgono powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prod3</intervention_name>
    <description>120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon</description>
    <arm_group_label>Prod3</arm_group_label>
    <other_name>G7 Aloe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults men or women (&gt;18 years old)

          -  With normal serum creatinine levels.

          -  Written informed consent provided before the initial screening visit.

        Exclusion Criteria:

          -  Suffering from chronic diseases

          -  Suffering from intestinal disorders

          -  Consuming silicon supplements in the 7 days prior to inclusion in the study.

          -  Consuming medicines containing silicon in the 7 days prior to inclusion in the study.

          -  Current or past participation in a clinical trial or consumption of a research product
             in the 30 days prior to inclusion in the study.

          -  Failing to follow study guidelines.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rosa Maria Valls, PhD</last_name>
    <phone>+34 636 944 723</phone>
    <email>estudis@ctns.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Technological Centre of Nutrition and Health (CTNS)</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Maria Valls, PhD</last_name>
      <phone>+34 636 944 723</phone>
      <email>estudis@ctns.cat</email>
    </contact>
    <contact_backup>
      <last_name>Ignasi Papell, BSc</last_name>
      <phone>+34 977 300 431</phone>
      <email>estudis@ctns.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Pedret, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ctns.cat/en</url>
    <description>Technological Centre of Nutrition and Health</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silicon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

